Influence of efflux transporters on drug metabolism: Theoretical approach for bioavailability and clearance prediction

Clinical Pharmacokinetics

Volumn 50, Issue 2, 2011, Pages 75-80

  Fagiolino, Pietro ^a   Vázquez, Marta ^a   Eiraldi, Rosa ^a   Maldonado, Cecilia ^a   Scaramelli, Alejandro ^a  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; MULTIDRUG RESISTANCE PROTEIN 2; PHENOBARBITAL; PHENYTOIN; PREGNANE X RECEPTOR;

ARTICLE; BIOTRANSFORMATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INTESTINES; LIVER; MEMBRANE TRANSPORT PROTEINS; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; MODELS, THEORETICAL;

EID: 78751481403     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11539230-000000000-00000     Document Type: Article

References (25)

1. Fagiolino P. Multiplicative dependence of the first order rate constant and its impact on clinical pharmacokinetics and bioequivalence. Eur J Drug Metab Pharmacokinet 2004; 29: 43-9.
2. Fagiolino P, Eiraldi R, Vazquez M.The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships. Clin Pharmacokinet 2006; 45: 433-48.
3. Fagiolino P, Wilson F, Samaniego E, et al. In vitro approach to study the influence of the cardiac output distribution on drug concentration. Eur J Drug Metab Pharmacokinet 2003; 28: 147-53.
4. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36 Suppl. 5: S8-13.
5. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2007; 46: 271-9.
6. von Richter O, Burk O, Fromm MF, et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepa-tocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-83.
7. Fagiolino P, Vazquez M, Olano I, et al. Systemic and presystemic conversion of carbamazepine to carbamazepine-10,11-epoxide during long term treatment. J Epilepsy Clin Neurophysiol 2006; 12: 13-6.
8. Geissmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 2004; 76: 192-200.
9. Couture L, Nash JA, Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev 2006; 58: 244-58.
10. Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003; 306: 124-31.
11. Bernus I, Dickinson RG, Hooper WD, et al. Dose-dependent metabolism of carbamazepine in humans. Epilepsy Res 1996; 24: 163-72.
12. Battino D, Croci D, Rossini A, et al. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia 2003; 44: 923-9.
13. Eadie MJ, Tyrer JH, Bochner F, et al. The elimination of phenytoin in man. Clin Exp Pharmacol Physiol 1976; 3: 217-24.
14. Cusack BJ, Tesnohlidek DA, Loseke VL, et al. Phenytoin pharmacokinetics in the rabbit: evidence of rapid autoinduction. Res Commun Chem Pathol Pharmacol 1987; 58: 269-72.
15. Dickinson RG, Hooper WD, Patterson M, et al. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit 1985; 7: 283-9.
16. Lapple F, von Richter O, Fromm MF, et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003; 13: 565-75.
17. Lombardo L, Pellitteri R, Balazy M, et al. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res 2008; 5: 82-92.
18. Alvin J, McHorse T, Hoyumpa A, et al. The effect of liver disease in man on the disposition of phenobarbital. J Pharmacol Exp Ther 1975; 192: 224-35.
19. Abramson FP. Autoinduction of phenobarbital elimination in dog. J Pharm Sci 1988; 77: 768-70.
20. Browne TR, Evans JE, Szabo GK, et al. Studies with stable isotopes II: pheno- barbital pharmacokinetics duringmonotherapy.JClinPharmacol 1985; 25:51-8.
21. Wiswanathan CT, Booker HE, Welling PG. Pharmacokinetics of pheno- barbital following single and repeated doses. J Clin Pharmacol 1979; 19: 282-9.
22. Lockard JS, Levy RH, Uhlir V, et al. Interactions of phenytoin and pheno- barbital in terms of order and temporal spacingofadministration in monkeys. Epilepsia 1976; 17: 481-5.
23. Launay-Vacher V, Izzedine H, Karie S, et al. Renal tubular drug transporters. Nephron Physiol 2006; 103: 97-106.
24. Lazarowski A, Czomyj L, Lubieniecki F, et al. Multidrug-resistance (MDR) protein develops refractory epilepsy phenotype: clinical and experimental evidences. Current Drug Ther 2006; 1: 291-309.
25. Maldonado C, Fagiolino P, Vazquez M, et al. Therapeutic carbamazepine (CBZ) and valproic acid (VPA) monitoring in children using saliva as a biologic fluid. J Epilepsy Clin Neurophysiol 2008; 14: 55-8